PTPN11 and ovarian cancer: Furthermore, single sample GSEA (ssGSEA) [30] comparisons for 23 cisplatin-treated (GSE146965) and six carboplatin-treated (GSE15622) ovarian cancer patients (pre- and -post-treatment) revealed significant enrichment of WNT/β-catenin and SHP2 signaling pathways (Fig. 1C).